Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 180
interventional 163
Observational 15
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 71
Drug|Other 21
Biological 8
Biological|Other 7
Biological|Drug 6
Drug|Other|Procedure|Radiation 5
Drug|placebo 5
Drug|Procedure 5
Biological|Drug|Procedure|Radiation 4
Other 4
Biological|Drug|Other 3
Biological|Drug|Other|Procedure|Radiation 3
Biological|Drug|Other|Procedure 2
Dietary Supplement|Drug 2
Drug|Other|Procedure 2
Drug|Procedure|Radiation 2
Drug|Radiation 2
Other|Procedure 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic|Other 1
Biological|Other|Procedure 1
Biological|Procedure|Radiation 1
Device|Drug 1
Device|Other 1
Drug|Genetic|Other 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 114
United States|Italy 5
Japan 3
NA 3
United States|Canada 3
United States|Germany|Italy 3
France 2
Korea, Republic of 2
United Kingdom 2
Austria 1
Austria|Belgium|France|Germany|Greece|Italy|Japan|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
Austria|France|Germany|Switzerland 1
China 1
Germany 1
Norway 1
Spain|Switzerland 1
United States|Argentina|Australia|Belgium|Canada|Finland|France|Germany|Hungary|Italy|Spain|Switzerland 1
United States|Australia 1
United States|Australia|Austria|Belgium|Brazil|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Netherlands|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Austria|Finland|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Italy|Spain|United Kingdom 1
United States|Australia|Denmark|France|Germany|Italy|Japan|Netherlands|Spain|Switzerland|United Kingdom 1
United States|Australia|Puerto Rico 1
United States|Belgium|France|Italy|Spain|United Kingdom 1
United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan 1
United States|France|Germany 1
United States|France|Germany|Italy|Spain|United Kingdom 1
United States|France|Germany|Poland|Russian Federation|United Kingdom 1
United States|France|Germany|Portugal|Spain|United Kingdom 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|France|Netherlands|United Kingdom 1
United States|Germany 1
United States|Germany|Sweden|United Kingdom 1

Sites per Study

Site_count Study_Count
1 88
2 10
3 6
4 2
5 12
6 1
7 5
8 1
9 1
10 4
11 5
12 1
13 2
16 2
17 1
18 1
19 1
20 4
21 3
22 1
23 1
27 1
33 1
34 2
35 1
41 2
43 1
44 1
62 1
73 1

Phase

Phase Study_Count
Phase 2 62
Phase 1 52
Phase 1/Phase 2 20
N/A 13
Phase 3 6
Phase 4 6
Early Phase 1 2
Phase 2/Phase 3 2

Number of Arms

Number_of_Arms Count_of_Studies
1 111
2 22
3 7
4 2
5 1
6 2
7 1
8 1
NA 16

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 8.00 5.0 2.00000 13.00000 1.00000 9.0 115.0000 7.00
1st Qu. 14.25 20.0 18.00000 20.50000 25.00000 41.5 138.2500 22.25
Median 20.50 62.5 30.00000 37.00000 43.00000 74.0 164.5000 59.50
Mean 20.50 115.0 35.47059 50.73684 56.72131 74.0 380.6667 69.50
3rd Qu. 26.75 163.5 54.50000 61.50000 74.00000 106.5 321.2500 79.50
Max. 33.00 495.0 111.00000 177.00000 250.00000 139.0 1337.0000 195.00

Trial Group Type

group_type Group_Count
Experimental 198
NA 16
Active Comparator 10
Placebo Comparator 4
No Intervention 2
Other 1
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 127
Parallel Assignment 24
Sequential Assignment 5
NA 5
Crossover Assignment 1
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 150
Supportive Care 9
Diagnostic 3
Other 1

Observational Studies

Studies by Country

Country Study_Count
United States 13
France 1
United States|Australia|Canada|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 14
130 1

Enrollment Metrics

Measure Observational
Min 6.0
1st Qu 28.5
Median 100.0
Mean 222.2
3rd Qu 250.0
Max 1263.0

Observation Model

observational_model Study_Count
Case-Only 4
NA 4
Cohort 3
Other 3
Case-Control 1

Time Perspective

time_perspective Study_Count
Prospective 11
Retrospective 2
NA 2

Registries

Studies by Country

Country Study_Count
Spain 1
United States 1

Sites per Study

Site_count Study_Count
14 1
36 1

Enrollment Metrics

Measure Registries
Min 300
1st Qu 725
Median 1150
Mean 1150
3rd Qu 1575
Max 2000

Registry Model

observational_model Study_Count
Cohort 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
10 Years 1
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03409432 Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03409432 Recruiting Ohio State University Comprehensive Cancer Center 2021-04-30
NCT03380026 Mechlorethamine Induced Contact Dermatitis Avoidance Study https://ClinicalTrials.gov/show/NCT03380026 Recruiting Rochester Skin Lymphoma Medical Group, PLLC 2019-12-13
NCT03357224 PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT03357224 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-09-30
NCT03340155 Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases https://ClinicalTrials.gov/show/NCT03340155 Recruiting Medical University of Graz 2022-10-31
NCT03292406 A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT03292406 Active, not recruiting Galderma R&D 2020-09-30
NCT03278782 Study of Pembrolizumab (MK-3475) in Combination With Romidepsin https://ClinicalTrials.gov/show/NCT03278782 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03218683 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. https://ClinicalTrials.gov/show/NCT03218683 Active, not recruiting AstraZeneca 2022-01-11
NCT03192202 AFM13 in Relapsed/Refractory Cutaneous Lymphomas https://ClinicalTrials.gov/show/NCT03192202 Recruiting Columbia University 2020-08-31
NCT03116659 CTCL Directed Therapy https://ClinicalTrials.gov/show/NCT03116659 Recruiting James J. Peters Veterans Affairs Medical Center 2020-12-30
NCT03109353 Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT03109353 Active, not recruiting St. Olavs Hospital 2020-09-30
NCT03017820 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03017820 Recruiting Mayo Clinic 2021-01-15
NCT03011814 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03011814 Recruiting City of Hope Medical Center 2023-03-08
NCT02978625 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers https://ClinicalTrials.gov/show/NCT02978625 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT02689453 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) https://ClinicalTrials.gov/show/NCT02689453 Recruiting National Institutes of Health Clinical Center (CC) 2023-01-31
NCT02676778 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02676778 Completed Eisai Inc. 2019-04-24
NCT02643303 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers https://ClinicalTrials.gov/show/NCT02643303 Recruiting Ludwig Institute for Cancer Research 2022-08-31
NCT02616965 A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02616965 Recruiting Fox Chase Cancer Center 2021-12-31
NCT02593045 Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) https://ClinicalTrials.gov/show/NCT02593045 Active, not recruiting Innate Pharma 2019-12-31
NCT02576496 Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02576496 Recruiting Mundipharma-EDO GmbH 2021-03-31
NCT02567656 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02567656 Completed Rhizen Pharmaceuticals SA 2018-03-31
NCT02546440 Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT02546440 Recruiting Universitätsmedizin Mannheim 2020-09-30
NCT02542124 NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) https://ClinicalTrials.gov/show/NCT02542124 Active, not recruiting Neumedicines Inc. 2019-02-28
NCT02520791 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02520791 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02512497 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02512497 Recruiting Ohio State University Comprehensive Cancer Center 2020-12-31
NCT02448381 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) https://ClinicalTrials.gov/show/NCT02448381 Active, not recruiting Soligenix 2019-12-31
NCT02342782 Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02342782 Active, not recruiting City of Hope Medical Center 2020-12-31
NCT02341209 Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02341209 Recruiting Rochester General Hospital 2020-02-06
NCT02232516 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02232516 Recruiting Northwestern University 2022-07-31
NCT02192021 Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT02192021 Recruiting University of Pittsburgh 2021-12-31
NCT03385226 A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) https://ClinicalTrials.gov/show/NCT03385226 Recruiting University College, London 2022-01-31
NCT02181218 Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT02181218 Active, not recruiting Washington University School of Medicine 2019-03-28
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02811783 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL https://ClinicalTrials.gov/show/NCT02811783 Recruiting Elorac, Inc. 2022-06-30
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01902225 Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01902225 Completed University of California, San Francisco 2018-07-13
NCT01871727 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01871727 Recruiting Eisai Inc. 2021-03-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01804335 CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01804335 Completed M.D. Anderson Cancer Center 2015-03-31
NCT01800838 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01800838 Completed Case Comprehensive Cancer Center 2014-09-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01728805 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL https://ClinicalTrials.gov/show/NCT01728805 Active, not recruiting Kyowa Kirin Pharmaceutical Development, Inc. 2017-03-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01676831 Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01676831 Completed Abramson Cancer Center of the University of Pennsylvania 2015-01-31
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01638533 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction https://ClinicalTrials.gov/show/NCT01638533 Active, not recruiting National Cancer Institute (NCI) 2018-11-29
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01578499 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) https://ClinicalTrials.gov/show/NCT01578499 Completed Takeda 2016-05-31
NCT01569724 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01569724 Completed Rennes University Hospital 2016-12-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01486277 A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01486277 Completed Janssen Research & Development, LLC 2014-11-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01433731 Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01433731 Completed TetraLogic Pharmaceuticals 2013-09-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01396070 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level https://ClinicalTrials.gov/show/NCT01396070 Completed Stanford University 2015-04-30
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01352520 SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) https://ClinicalTrials.gov/show/NCT01352520 Active, not recruiting M.D. Anderson Cancer Center 2021-01-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04362007 A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04362007 Recruiting Otsuka Pharmaceutical Co., Ltd. 2024-09-30
NCT04296786 Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study https://ClinicalTrials.gov/show/NCT04296786 Recruiting Peking Union Medical College Hospital 2022-12-31
NCT04045470 A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT04045470 Recruiting Dana-Farber Cancer Institute 2023-01-01
NCT03902184 IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03902184 Recruiting Innate Pharma 2022-03-01
NCT03837457 PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study https://ClinicalTrials.gov/show/NCT03837457 Enrolling by invitation miRagen Therapeutics, Inc. 2021-12-31
NCT03775525 Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT03775525 Recruiting Genzada Pharmaceuticals USA, Inc. 2020-09-30
NCT03713320 SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03713320 Active, not recruiting miRagen Therapeutics, Inc. 2021-04-30
NCT03602157 Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL https://ClinicalTrials.gov/show/NCT03602157 Recruiting UNC Lineberger Comprehensive Cancer Center 2026-09-30
NCT03601819 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT03601819 Recruiting University of Michigan Rogel Cancer Center 2021-09-30
NCT03493451 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms https://ClinicalTrials.gov/show/NCT03493451 Active, not recruiting BeiGene 2021-02-28
NCT03487133 Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03487133 Recruiting Samsung Medical Center 2020-12-31
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01226472 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 https://ClinicalTrials.gov/show/NCT01226472 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2012-09-30
NCT01198665 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01198665 Completed Samsung Medical Center 2014-12-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01134341 Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01134341 Completed Acrotech Biopharma LLC 2015-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01129180 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01129180 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01007448 Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01007448 Completed Bausch Health Americas, Inc. 2014-02-20
NCT00961220 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00961220 Completed National Cancer Institute (NCI) 2012-04-08
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00896493 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00896493 Active, not recruiting Stanford University 2022-12-31
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT04171791 A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT04171791 Recruiting Yale University 2021-02-28
NCT00807495 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00807495 Completed Takeda 2011-01-04
NCT02953301 Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) https://ClinicalTrials.gov/show/NCT02953301 Recruiting 4SC AG 2022-01-31
NCT02580552 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL https://ClinicalTrials.gov/show/NCT02580552 Active, not recruiting miRagen Therapeutics, Inc. 2020-12-31
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT00771472 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) https://ClinicalTrials.gov/show/NCT00771472 Completed Merck Sharp & Dohme Corp. 2011-07-31
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00748319 Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00748319 Completed Assistance Publique - Hôpitaux de Paris 2011-11-30
NCT00744991 A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00744991 Completed Eli Lilly and Company 2010-01-31
NCT00660231 Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00660231 Completed University College, London 2011-09-30
NCT00611208 A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00611208 Completed Angimmune LLC 2015-02-28
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00554827 Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00554827 Completed Acrotech Biopharma LLC 2012-01-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00506129 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00506129 Completed M.D. Anderson Cancer Center 2015-06-30
NCT00501735 Forodesine in the Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00501735 Completed BioCryst Pharmaceuticals 2010-07-31
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00490776 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00490776 Completed Novartis 2009-09-30
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00438802 Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00438802 Completed Mayo Clinic 2010-08-24
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT00431912 A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00431912 Completed Onxeo 2011-01-31
NCT00425555 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00425555 Completed Novartis 2013-06-30
NCT00412997 LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00412997 Completed Novartis 2008-05-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00306969 Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00306969 Completed Boston University NA
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00255801 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00255801 Completed Memorial Sloan Kettering Cancer Center 2017-10-31
NCT00221039 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A https://ClinicalTrials.gov/show/NCT00221039 Completed M.D. Anderson Cancer Center 2011-04-05
NCT00211198 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00211198 Completed Eisai Inc. 2005-01-31
NCT00182637 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00182637 Completed Jonsson Comprehensive Cancer Center 2010-09-30
NCT00178841 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL https://ClinicalTrials.gov/show/NCT00178841 Completed Vanderbilt University 2007-03-31
NCT00131937 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00131937 Completed National Cancer Institute (NCI) 2011-09-30
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00106431 A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00106431 Completed Celgene 2008-06-01
NCT00099593 Immunization Against Tumor Cells in Sezary Syndrome https://ClinicalTrials.gov/show/NCT00099593 Completed FDA Office of Orphan Products Development NA
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00098332 Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00098332 Completed National Cancer Institute (NCI) 2010-12-31
NCT00091559 Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) https://ClinicalTrials.gov/show/NCT00091559 Completed Merck Sharp & Dohme Corp. 2005-11-23
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00005080 506U78 in Treating Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00005080 Completed National Cancer Institute (NCI) 2006-01-31
NCT00080535 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00080535 Completed National Institutes of Health Clinical Center (CC) 2011-12-31
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00071084 Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. https://ClinicalTrials.gov/show/NCT00071084 Completed Emergent Product Development Seattle LLC 2004-06-30
NCT00071071 Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. https://ClinicalTrials.gov/show/NCT00071071 Completed Emergent Product Development Seattle LLC 2004-05-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00061880 BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00061880 Completed National Cancer Institute (NCI) 2005-01-31
NCT00050999 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients https://ClinicalTrials.gov/show/NCT00050999 Completed Eisai Inc. 2006-09-30
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00030849 Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00030849 Completed National Cancer Institute (NCI) 2004-09-30
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00020072 Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells https://ClinicalTrials.gov/show/NCT00020072 Completed National Cancer Institute (NCI) NA
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00051012 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT00051012 Completed Eisai Inc. 2006-10-31
NCT00001249 Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac https://ClinicalTrials.gov/show/NCT00001249 Completed National Institutes of Health Clinical Center (CC) NA
NCT00043420 CPG 7909 in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00043420 Completed Pfizer 2007-03-31
NCT00038025 A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00038025 Completed M.D. Anderson Cancer Center 2006-11-29
NCT00051597 A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00051597 Completed Seattle Genetics, Inc. NA
NCT00007345 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00007345 Completed National Institutes of Health Clinical Center (CC) 2015-01-26

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02840747 Tissue Repository: CTCL Collection Protocol https://ClinicalTrials.gov/show/NCT02840747 Recruiting Columbia University 2021-01-31
NCT01087333 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment https://ClinicalTrials.gov/show/NCT01087333 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00341939 Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data https://ClinicalTrials.gov/show/NCT00341939 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT02520908 Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis https://ClinicalTrials.gov/show/NCT02520908 Recruiting Assistance Publique - Hôpitaux de Paris 2021-09-30
NCT02296398 Long-term Use of Romidepsin in Patients With CTCL https://ClinicalTrials.gov/show/NCT02296398 Completed Northwestern University 2015-07-31
NCT01460914 Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment https://ClinicalTrials.gov/show/NCT01460914 Active, not recruiting Dartmouth-Hitchcock Medical Center 2050-09-30
NCT03932279 Characterization of the Microbiome in Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03932279 Recruiting Northwestern University 2020-12-31
NCT03789864 Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03789864 Recruiting Indiana University 2021-05-01
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT02836886 VircapSeq Virus Detection in Sézary Syndrome https://ClinicalTrials.gov/show/NCT02836886 Completed Columbia University 2016-10-31
NCT00430053 Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00430053 Completed National Institutes of Health Clinical Center (CC) NA
NCT00254332 Effect of Denileukin Diftitox on Immune System in CTCL Patients https://ClinicalTrials.gov/show/NCT00254332 Completed FDA Office of Orphan Products Development NA
NCT00177268 Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research https://ClinicalTrials.gov/show/NCT00177268 Recruiting University of Pittsburgh 2027-01-31
NCT00177190 In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00177190 Completed University of Pittsburgh 2005-01-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02296164 Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02296164 Completed Helsinn Therapeutics (U.S.), Inc 2018-10-17
NCT03646422 AEDV Registry of Primary Cutaneous Lymphoma https://ClinicalTrials.gov/show/NCT03646422 Recruiting Fundación Academia Española de Dermatología 2025-01-01